Nevertheless, besides the known differences in clinicopathological features in breast cancer cases associated with germline BRCA1 or BRCA2 pathogenic variants9–12, there is a lack of evidence so far on whether the type of mutated gene may also lead to potential differences in breast cancer clinical behavior and outcomes. The gene discussed is BRCA1; the disease is breast carcinoma.